Orlando, FL-Most long-term survivors of metastatic renal cellcarcinoma do not achieve a response to cytokine treatment, according toresults of a pooled analysis by French researchers. Their findings suggesta lack of association between initial tumor regression on cytokine treatmentand long-term survival, except for the few patients who achieve completeregression.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.